EXAS vs SEPN · rev $2.76B vs rev $46.0M
EXACT Sciences Corporation (EXAS) versus Septerna, Inc. Common Stock (SEPN) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Septerna, Inc. Common Stock (SEPN) is a biotechnology company listed on NASDAQ.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
Latest reported SEPN revenue for 2025-12-31 was $46.0M. Net income was -$48.9M. Revenue was up 4174.5% from 2024-12-31 to 2025-12-31. SEPN currently screens at market cap $1.61B.
EXAS currently screens at market cap $20.03B. SEPN currently screens at market cap $1.61B.
Not investment advice. Open the EXAS and SEPN stock pages for the full models.
Not investment advice.